Ceisteanna ar Pholasaí nó ar Reachtaíocht - Questions on Policy or Legislation
Dail Éireann — 2026-04-29
============================================================

Marie Sherlock (LAB), Dublin Central

I want to ask about the national vaccination programme. Yesterday, HIQA issued its health technology assessment on the respiratory syncytial virus, RSV, vaccine stating that it is clinically effective for small babies but that the cost is too much to continue the mass roll-out. Last week, we had officials from the HSE and the Department of Health tell us that they very much believe in the clinical effectiveness of the shingles vaccine but, again, HIQA has stated that it is too expensive. Last winter, HIQA also talked about the clinical effectiveness of the enhanced flu vaccine but, again, cost was an obstacle.
Vaccines are crucial to public health and to reducing health inequality. The shingles vaccine costs over €500. In the context of cost being the issue, of course we need to drive a hard bargain with the pharmaceutical companies. In that context, why was there no reference to vaccines in the framework agreement reached with pharmaceutical companies in March? The latter is a three-year agreement governing the sale of drugs to this country. Is there no emphasis on future vaccines on the part of the Government?

---

Source: Houses of the Oireachtas. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The Official Report is revised after first publication; the fetch timestamp below identifies the version quoted.

Record URI: https://data.oireachtas.ie/akn/ie/debateRecord/dail/2026-04-29/debate/main
Retrieved: 2026-09-21T01:01:08+00:00
Sitting date: 2026-04-29